Related references
Note: Only part of the references are listed.SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
Yukihiro Chino et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2014)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
Paul Nyirjesy et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
Matthew R. Weir et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes
Mohammed Iqbal Hawa et al.
DIABETES CARE (2014)
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Michaela Diamant et al.
DIABETES CARE (2014)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2014)
Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis
O. J. Phung et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis
S. Goring et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
P. -H. Groop et al.
DIABETES OBESITY & METABOLISM (2014)
The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial
W. Lane et al.
DIABETES OBESITY & METABOLISM (2014)
High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7)
Simona Zampetti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
Bernard Charbonnel et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Pioglitazone use and the risk of bladder cancer
Hsin-Wei Kuo et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2014)
Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment
Amy G. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
Bruce Neal et al.
AMERICAN HEART JOURNAL (2013)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Unleash Metformin: Reconsideration of the Contraindication in Patients with Renal Impairment
Wenya R. Lu et al.
ANNALS OF PHARMACOTHERAPY (2013)
Pioglitazone and bladder cancer: a propensity score matched cohort study
Li Wei et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
David M. Nathan et al.
DIABETES CARE (2013)
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
Guntram Schernthaner et al.
DIABETES CARE (2013)
Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
R. Balena et al.
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
W. B. White et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
Kristina M. Johnsson et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
Giovanni Musso et al.
ANNALS OF MEDICINE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. E. Inzucchi et al.
DIABETOLOGIA (2012)
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
H. M. Colhoun et al.
DIABETOLOGIA (2012)
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ele Ferrannini et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes A Randomized, Controlled Trial
John B. Buse et al.
ANNALS OF INTERNAL MEDICINE (2011)
Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
Faramarz Ismail-Beigi et al.
ANNALS OF INTERNAL MEDICINE (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Kasia J. Lipska et al.
DIABETES CARE (2011)
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
E. Bosi et al.
DIABETES OBESITY & METABOLISM (2011)
Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes
P. K. Shah et al.
DIABETES OBESITY & METABOLISM (2011)
A STEPWISE APPROACH TO INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND BASAL INSULIN TREATMENT FAILURE
Mayer B. Davidson et al.
ENDOCRINE PRACTICE (2011)
Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?
Helen J. Nye et al.
NEPHRON CLINICAL PRACTICE (2011)
U-500 Regular Insulin - Clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients
Mayer B. Davidson et al.
DIABETES CARE (2010)
Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
J. Michael Gaziano et al.
DIABETES CARE (2010)
Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19)
Bernard Charbonnel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Review: Metformin: Potential benefits and use in chronic kidney disease
Helen L. Pilmore
NEPHROLOGY (2010)
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Shelley R. Salpeter et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
George L. Bakris et al.
KIDNEY INTERNATIONAL (2009)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
